The Conversation (0)
Miraculins Inc. (TSXV:MOM) detailed its plans for the Scout DS in 2015, highlighting the following priorities: develop primary sales and distribution channels, advance chinese SFDA clearance, establish manufacturing, proceed on US FDA clearance submissions, and appoint a Scout DS Medical Advisory board.
As quoted in the press release:
“Pursuing Chinese FDA Approval, establishing full production capabilities, and establishing proof of concept for various revenue models will be the primary focus of our Scout DS® activity in 2015,” said Christopher J. Moreau, President and CEO of Miraculins. “Diabetes is being described now as the world’s fastest growing disease and Miraculins is well-positioned with its proprietary Scout DS® technology to make a significant impact on screening for pre-diabetes and type 2 diabetes and moving at-risk patients on to their physicians for confirmatory testing, diagnosis, and treatment.”
Click here to read the Miraculins Inc. (TSXV:MOM) press release
Click here to see the Miraculins Inc. (TSXV:MOM) profile.